Eli Lilly’s (NYSE:LLY) experimental obesity therapy eloralintide has caused up to 11% weight loss over 12 weeks in an ...

Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company, The Home Depot and ...

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Eli Lilly's experimental obesity drug, eloralintide, helped some patients lose 11.5% of their body weight at 12 weeks in an ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Juvena Therapeutics & Eli Lilly and Company ink research collaboration focused on muscle health: Redwood City, California Saturday, June 14, 2025, 15:00 Hrs [IST] Juvena Therapeut ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly and Company ( NYSE: LLY) Goldman Sachs 46th Annual Global Healthcare Conference June 10, 2025 8:00 AM ET Lucas E. Montarce - Executive VP & CFO Michael Czapar - Director of Investor ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

Eli Lilly & Co. and health tech company Kalderos Inc. are seeking to revive lawsuits in the DC Circuit after a federal judge ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...